With our technology, patients whose files need to be reviewed in priority are automatically identified by an alert score. The higher the score, the more important it is to review the file, because the chances of success of an intervention are that much higher. Rather than reviewing all 200 patients who receive antibiotics, the pharmacist looks at around forty, using a strategy supported by software that gathers all the information required for a good review of the file.
– Vincent Nault, President, LUMED

LUMED, a software development company dedicated to improving hospital care, was born in Sherbrooke in 2012. It started a few years earlier as part of a research project on the optimal use of antibiotics to treat infectious diseases, particularly by avoiding their overuse.

The wide range of medical and computer skills of the three founders Louis Valiquette, Mathieu Beaudoin and Vincent Nault, has led to the design of the world’s most effective antibiotic stewardship system: the subject of various publications, widely recognized by pharmacists and infectious disease specialists, and winner of several awards for innovation.

The company’s flagship software, APSS, tracks the progress of hospitalized patients over time and identifies potential improvements to their treatments. The positive impacts of this software affect both patients and hospital administration, as well as the use of resources involved in the treatment process.

To develop and commercialize its software, LUMED has benefited from the support of various provincial research funds, such as the NSERC, FRQS, MEDTEQ, Canada Economic Development and the Business Development Bank of Canada. The company was also chosen by Université de Sherbrooke’s tech company accelerator (ACET), an incubator designed to guide software development among start-up companies, to enable them to achieve growth, by, for example, helping to secure financing.

A tried and tested product

Thanks to their various partners who believe in the quality of their innovative products, LUMED’s current team of nine is likely to grow over the next 18 months.

On the day of our interview, the company announced an international alliance with bioMérieux, an in vitro diagnostics specialist. The challenge for LUMED will be to bridge all the data produced by bioMérieux with the patient’s bedside care. “If new information on the patient’s context requires a treatment adjustment, our system generates alerts that advise clinicians to respond based on the newly available information,” explains Vincent.

“For us, this partnership highlights the fact that the world leader in microbiology diagnostics looked at all the competing software from around the world and determined that our technology was the most effective in meeting the needs of clinicians,” the co-founder proudly asserts. Accordingly, LUMED’s chances of penetrating numerous markets in Europe and North America are greatly increased.

It’s no wonder that their technology is gaining ground on the international scene: its long-term use has been shown to produce sustained savings of $350,000 per year in drug purchases (representing about 30% of a hospital’s antibiotics budget), in addition to the drastic cost reduction associated with shortened lengths of stay. In addition, the overall decrease of 20% in antibiotic consumption helps to minimize the emergence of resistant bacteria.

Innovating every day…

The Centre hospitalier universitaire de Sherbrooke is a major partner of LUMED, who collaborates with its research centre on an ongoing basis. The company is currently involved in a number of new projects, such as a drug management platform for intensive care, oncology research and infection prevention.

With a broad range of applications for its technology, LUMED’s biggest challenge is to convince hospital IT teams to collaborate on the implementation of its solution. “It’s not something you can put on a CD and give to a pharmacist to install on their computer,” indicates Vincent. “It’s a sizeable implementation and our challenge is to get the IT teams on board. The benefits of this technology aren’t necessarily obvious to them because they’re not the ones who will be using it. So we need to find the right people to lead the project internally and get the support we need to make it a success.”

With its growing reputation in Quebec and around the world, LUMED will surely be able to overcome this kind of obstacle!

Source: Mélanie Pilon, writer for the Vitrine Star Tech

Be a part of technopolys!

04Apr 2018

If major companies like TransferWise, Wealthsimple and one of the ten largest financial institutions in the country do business with us, it’s mainly because we really focus on the quality of the data we make available to them and the speed of our application.
– Yves-Gabriel Lebœuf, CEO and Co-founder of Flinks

Combining the words financial and links, Flinks is a financial data aggregation application that facilitates the connection between financial institutions and the various software companies that use this data as part of the services they offer.

Yves-Gabriel gives the example of Paypal, which must be linked to users’ bank accounts to allow deposits and withdrawals. “Previously, people had to submit all the numbers required to tell the system which institution, transit and account to use,” he explains. “With the technology we’ve developed, we do that instantly. Then, our clients choose our API because of the reliability and stability of the connection from which the financial data is drawn.”

Continue reading

28Mar 2018

The end users of our product – a product that bridges the real world and the web – never feel observed, for example, by their employer. Instead, they are requesting the kind of recognition our technology offers because it improves their experience. That’s a huge win for us.
– Jeffrey Dungen, Co-founder and CEO of reelyActive

reelyActive, a world leader in BYOD (Bring Your Own Device) real-time location systems, allows their clients to view the real world as if it were made up of webpages, in order to optimize what matters most to their business.

Continue reading

16Mar 2018

Thanks to this reciprocal agreement, clients of CEIM and of WBC will benefit from the services offered by the Liège or Montréal incubators under the same conditions as if they were clients of the partner incubator.
– Serge Bourassa, President and Chief Operations Officer, CEIM

To support entrepreneurship in life sciences, Centre d’entreprises et d’innovation de Montréal (CEIM) and WBC Incubator, based in Liège, Belgium, signed a cooperation agreement.

Continue reading